Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Daniel LaBarbera to Cell Line, Tumor

This is a "connection" page, showing publications Daniel LaBarbera has written about Cell Line, Tumor.

 
Connection Strength
 
 
 
1.313
 
  1. Esquer H, Zhou Q, LaBarbera DV. Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer. Cells. 2025 02 20; 14(5).
    View in: PubMed
    Score: 0.130
  2. Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, Zhou Q, Messersmith WA, LaBarbera DV. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. Int J Mol Sci. 2024 Dec 07; 25(23).
    View in: PubMed
    Score: 0.128
  3. Sala R, Esquer H, Kellett T, Kearns JT, Awolade P, Zhou Q, LaBarbera DV. CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos. Int J Mol Sci. 2024 Aug 06; 25(16).
    View in: PubMed
    Score: 0.125
  4. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961.
    View in: PubMed
    Score: 0.105
  5. Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612.
    View in: PubMed
    Score: 0.093
  6. Esquer H, Zhou Q, Abraham AD, LaBarbera DV. Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discov. 2020 08; 25(7):734-743.
    View in: PubMed
    Score: 0.093
  7. Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203.
    View in: PubMed
    Score: 0.090
  8. Zhou Q, Abraham AD, Li L, Babalmorad A, Bagby S, Arcaroli JJ, Hansen RJ, Valeriote FA, Gustafson DL, Schaack J, Messersmith WA, LaBarbera DV. Topoisomerase IIa mediates TCF-dependent epithelial-mesenchymal transition in colon cancer. Oncogene. 2016 09 22; 35(38):4990-9.
    View in: PubMed
    Score: 0.070
  9. Li L, Zhou Q, Voss TC, Quick KL, LaBarbera DV. High-throughput imaging: Focusing in on drug discovery in 3D. Methods. 2016 Mar 01; 96:97-102.
    View in: PubMed
    Score: 0.068
  10. Li L, Abraham AD, Zhou Q, Ali H, O'Brien JV, Hamill BD, Arcaroli JJ, Messersmith WA, LaBarbera DV. An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIa and potent anticancer agent. Mar Drugs. 2014 Sep 19; 12(9):4833-50.
    View in: PubMed
    Score: 0.063
  11. Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen. 2012 Oct; 17(9):1211-20.
    View in: PubMed
    Score: 0.054
  12. Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, Schaack J, LaBarbera DV. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen. 2011 Feb; 16(2):141-54.
    View in: PubMed
    Score: 0.049
  13. LaBarbera DV, Modzelewska K, Glazar AI, Gray PD, Kaur M, Liu T, Grossman D, Harper MK, Kuwada SK, Moghal N, Ireland CM. The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs. 2009 Jul; 20(6):425-36.
    View in: PubMed
    Score: 0.044
  14. Klosowski ML, Cronise KE, Palmer EP, McAuliffe K, Stratton C, Sparks K, Malmstrom KT, Knott-Byars G, Zhou Q, Esquer H, LaBarbera DV, Regan DP. Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance. Proc Natl Acad Sci U S A. 2025 Nov 25; 122(47):e2423894122.
    View in: PubMed
    Score: 0.034
  15. Agarwal N, Zhou Q, Arya D, Rinaldetti S, Duex J, LaBarbera DV, Theodorescu D. AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer. Int J Mol Sci. 2022 Sep 16; 23(18).
    View in: PubMed
    Score: 0.027
  16. Agarwal N, Rinaldetti S, Cheikh BB, Zhou Q, Hass EP, Jones RT, Joshi M, LaBarbera DV, Knott SRV, Cech TR, Theodorescu D. TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proc Natl Acad Sci U S A. 2021 09 21; 118(38).
    View in: PubMed
    Score: 0.026
  17. Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
    View in: PubMed
    Score: 0.025
  18. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048.
    View in: PubMed
    Score: 0.021
  19. Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017 11 02; 36(44):6074-6084.
    View in: PubMed
    Score: 0.019
  20. Medellin DC, Zhou Q, Scott R, Hill RM, Frail SK, Dasari R, Ontiveros SJ, Pelly SC, van Otterlo WA, Betancourt T, Shuster CB, Hamel E, Bai R, LaBarbera DV, Rogelj S, Frolova LV, Kornienko A. Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities. J Med Chem. 2016 Jan 14; 59(1):480-5.
    View in: PubMed
    Score: 0.017
  21. Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb; 4(1):36-49.
    View in: PubMed
    Score: 0.014
  22. Hoang H, LaBarbera DV, Mohammed KA, Ireland CM, Skibo EB. Synthesis and biological evaluation of imidazoquinoxalinones, imidazole analogues of pyrroloiminoquinone marine natural products. J Med Chem. 2007 Sep 20; 50(19):4561-71.
    View in: PubMed
    Score: 0.010
  23. Lira SP, Vita-Marques AM, Seleghim MH, Bugni TS, LaBarbera DV, Sette LD, Sponchiado SR, Ireland CM, Berlinck RG. New destruxins from the marine-derived fungus Beauveria felina. J Antibiot (Tokyo). 2006 Sep; 59(9):553-63.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)